INTRODUCTION
Various types of transporters have been proposed to play important roles in the absorption of nutrients and xenobiotics in small intestine. For example, hydrophilic nutrients such as saccharides, oligopeptides and hydrophilic vitamins can only minimally penetrate through the plasma membrane by passive diffusion, and specific solute carriers (SLC) are involved in their transport into epithelial cells across the apical membrane. On the other hand, hydrophobic compounds, such as many therapeutic agents and other xenobiotics, are thought to be absorbed by passive diffusion, but some of them are actively pumped out by ATP binding cassettes (ABC) transporters, thereby hindering their oral absorption. SLC transporters localized on the apical membrane of small intestine often have relatively wide substrate specificity. Consequently it has been proposed that these SLC transporters play an important role in the import of not only nutrients, but also therapeutic agents into epithelial cells. Such SLC transporters may include oligopeptide transporter (PEPT1/SLC15A), organic anion transporting polypeptide 2B1 and 1A2 in humans (Glaeser et al., 2007; Groneberg et al., 2001; Kobayashi et al., 2003) .
The presence of such influx transporters has an impact on drug development, since it may be possible to utilize them to improve the oral absorption of therapeutic agents. For example, valaciclovir, the L-valyl ester of acyclovir, was developed as a prodrug of acyclovir
that is recognized as a substrate by PEPT1 (Balimane et al., 1998) . This is considered to be the reason for the greater bioavailability of valaciclovir than acyclovir (Soul-Lowton et al., 1995) . The recognition of various types of therapeutic agents by PEPT1 has led to utilization of this transporter in rational drug design (Brandsch, 2009; Li et al., 2008) . However, it is also important to consider influx transporter-mediated drug interactions (Banfield et al., 2002; Lilja et al., 2005a; 2005b) . Lilja et al. (2005a; 2005b) have reported decreased plasma concentration of several ß-blockers following ingestion of citrus juice. Subsequent studies in experimental animals confirmed the presence of small intestinal influx transporters for ß-blockers (Kato et al., 2009; Shirasaka et al., 2009 ). However, due to the presence of other mechanism(s) also affecting oral drug absorption, the contribution of influx transporters to the overall absorption of therapeutic agents remains to be fully clarified. In addition, possible involvement of influx transporters has been demonstrated only for relatively few therapeutic agents so far, and the mechanism of membrane permeation for most orally administered drugs
has not yet been clarified.
Carnitine/organic cation transporter OCTN1 (SLC22A4) was first identified in human fetal liver (Tamai et al., 1997) . It is ubiquitously distributed, being particularly highly expressed in the kidney, and is localized on the apical membrane of renal proximal tubular
epithelial cells (Tamai et al., 2000; Tamai et al., 2003) . OCTN1 transports several cationic compounds, including tetraethylammonium (TEA), pyrilamine, quinidine, verapamil, donepezil, betonicine, ergothionein (ERGO) and stachydrine (Yabuuchi et al., 1999; Grundemann et al., 2005) . Gründemann et al. reported that ERGO was most efficiently transported by OCTN1 heterologously transfected in a mammalian cell line in vitro (Gründemann et al., 2005 inside the lumen was recovered by manually washing the luminal side of each segment with 5 mL of ice-cold saline using a syringe and summing up the radioactivity recovered from the three segments. At 4 hr after the intravenous injection, the mice were decapitated, and tissues were excised immediately, rinsed with about 50 mL of ice-cold saline, blotted dry, weighed and solubilized with Solene-350® (Packard Inc., Meriden, CT) at 50°C for 3 hr. The solution was treated with hydrogen peroxide and neutralized with 5 M HCl. The associated radioactivity was measured with a liquid scintillation counter, LSC-5100 (Aloka, Tokyo, Japan), with Clearsol I (Nacalai Tesque, Inc., Kyoto, Japan) as the scintillation fluid.
Integration Plot Analysis
Mice were anesthetized with pentobarbital, and [ 3 H]ERGO (100 µg/kg) was injected via the left jugular vein. Blood was withdrawn from the right jugular vein at designated times, and plasma was separated by centrifugation. After 1, 2, 3 or 5 minutes, the mice were sacrificed, and liver was obtained and solubilized. The solubilized liver and plasma were each mixed with scintillation liquid, and the associated radioactivity was measured with a liquid scintillation counter as described above. Efflux from the liver soon after intravenous administration was assumed to be negligible, and the tissue uptake clearance (CL uptake ) was
calculated with the following equation:
where X T (t) and Cp(t) are the tissue amount and the plasma concentration at time t, respectively. AUC is the area under the plasma concentration-time curve. V 0 is the volume of distribution, within which a rapid equilibrium with the plasma compartment is assumed.
is plotted against
AUC Cp(t)
, the slope represents the value of CL uptake .
Uptake of [ 3 H]ERGO by Everted Intestinal Sac
The experimental procedure was as described previously (Nakashima et al., 1984) .
The freshly isolated small intestine was equally divided into upper, middle and lower segments. Each intestinal segment was everted with polyethylene tubing, and the everted sacs were washed with the buffer solution. After 5 min preincubation, the sacs were incubated with 
Transport Studies in HEK293/OCTN1 Cells
Plasmid DNA encoding mouse OCTN1 was transiently transfected into HEK293 cells according to the calcium phosphate precipitation method (Tamai et al., 2000) . At 48 hr after transfection, the HEK293/OCTN1 cells were harvested and suspended in the transport buffer (125 mM NaCl, 4.8 mM KCl, 5.6 mM D-glucose, 1.2 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , and 25 mM HEPES, pH 7.4). The uptake experiment was then performed according to the silicone oil layer method (Tamai et al., 2000) .
Isolation and Transport Experiments in Nonparenchymal Liver Cells
The separation of liver parenchymal and nonparenchymal cells was performed by the collagenase perfusion method (Berry and Friend, 1969; Horiuchi et al., 1985) with some modifications. Briefly, mice were anesthetized with pentobarbital, and their body temperature was maintained at 37˚C during the experiment. The liver was perfused first with Ca 2+ , Mg 2+ -free buffer from the inferior vena cava for 3 min, followed by perfusion buffer containing 5 mM CaCl 2 , 0.03% collagenase and 0.005% trypsin inhibitor for 10 min. As soon as the perfusion was started, the portal vein was cut, and the perfusion rate was maintained at This article has not been copyedited and formatted. The final version may differ from this version. mixture was 10-fold diluted with ice-cold transport buffer, then centrifuged for 1 min, and the supernatant was removed. The cells were washed three times with ice-cold buffer, followed by solubilization with NaOH. After solubilization, the cell lysate was neutralized with HCl.
The associated radioactivity was measured as described above. Cellular protein content was determined with a protein assay kit (Bio-Rad, Hercules, CA). The quantification of BSP was performed by HPLC (LC-10A series; Shimadzu, Kyoto, Japan). The reversed-phase column (COSMOSIL 5C 18 -AR-II, 4.6 x 150 mm; Nacalai Tesque, Kyoto, Japan) was maintained at 40˚C in a column oven. The mobile phase was a mixture of 20 mM potassium phosphate buffer (pH 6.0) and acetonitrile (70:30). The UV detector was set at 230 nm. The flow rate was 1.0 mL/min.
Immunohistochemical Studies and Western blot analysis
Mice were anesthetized and transcardially perfused with 4% paraformaldehyde (PFA). The liver and small intestine were removed and sequentially immersed in 4% PFA, 10, This article has not been copyedited and formatted. The final version may differ from this version. brush border membrane vesicles (BBMVs) were prepared according to the previous study (Sugiura et al., 2008) . Hepatic NPC, PC and HEK293/OCTN1 cells were obtained as described above. These samples were solubilized in RIPA-Y buffer containing 1% Nonidet P-40, 75 mM NaCl, 50 mM Tris-HCl, pH 7.5 and protease inhibitors. Solubilized samples were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), followed by immunoblotting with antisera against OCTN1. Western blot analysis was performed as described previously (Kato et al., 2005) . TEA or verapamil, both of which are substrates for OCTN1 ( Figure 3A) .
Characterization of the Uptake of [ 3 H]ERGO by OCTN1
The uptake of [ 
Expression and Localization of OCTN1 in Small Intestine
Localization of OCTN1 in the small intestine was next investigated by immunohistochemistry ( Figure 4A -J). OCTN1 was detected on apical region of epithelial cells in wild-type mice ( Figure 4A, 4E ), but not in octn1 -/-mice ( Figure 4C ). OCTN1 was also detected in the intestinal crypts ( Figure 4A ). Anti Na was also examined in human small intestine, and was again detected on the apical membrane ( Figure 5 ).
First-pass Uptake of [ 3 H]ERGO in Liver
Based on the data shown in Figures 1A, 2 showed only a minimal increase (Figure 7 ). CL uptake of [ 3 H]ERGO in wild-type mice was estimated to be 1.07 mL/min/g tissue, whereas that in octn1 -/-mice was 0.0145 mL/min/g tissue. Efficient hepatic uptake was also supported by the fact that the highest value of tissue-to-plasma concentration ratio (Kp) of [ 3 H]ERGO was measured at 4 hr after intravenous administration (Table 1 ). In addition to the liver, the Kp values of [ 3 H]ERGO in kidney, spleen, lung, heart, small intestine, large intestine, testis, pancreas, thymus and bone marrow of octn1 -/-mice were significantly lower than those in wild-type mice (Table 1) .
This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
ERGO is a natural thiol compound present in mushrooms and mammalian tissues (Ey et al., 2007) . Biosynthesis of ERGO occurs only in certain microorganisms, and so ERGO is presumably absorbed from daily foods in mammals. Since the membrane permeability of ERGO is expected to be limited due to its hydrophilicity, it is reasonable to speculate that a transporter is involved in its gastrointestinal absorption. However, there has been no report on the oral absorption mechanism of this compound. Here, we found that when The OCTN1-mediated ERGO uptake at small-intestinal apical membrane was inhibited by a therapeutic agent, verapamil (Figure 3 ). In view of the wide substrate specificity of OCTN1 (Yabuuchi et al., 1999; Grundemann et al., 2005) , the apical localization of this transporter both in humans and mice may require further consideration of the contribution of OCTN1 to oral absorption of other therapeutic agents; indeed, this transporter might be a novel target for rational design of orally administrable drugs. OCTN1
can act as an exchanger for H + and organic cations in OCTN1 gene-transfected HEK293 cells (Tamai et al., 2004) . On the other hand, some cationic compounds, such as cimetidine and guanidine, were reported to be transported via H + /cation exchange mechanisms across the brush border membranes in small intestine, but the transport properties seem not to be fully 
